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Abstract
Background: Rheumatoid arthritis (RA) patients are treated with a mean of 3–4 conventional synthetic disease-
modifying antirheumatic drugs (csDMARDs) with or without glucocorticoids (GCs), before the first biologic
prescription. The main reasons for change are inefficacy in 30–40 % of patients, and toxicity ≈ 10 %. Thus, they
are treated with the first TNF antagonists in monotherapy. The aim of this study was to analyse the csDMARD
and GC prescription patterns before and during treatment with the first TNF antagonist, and compare their
effectiveness in three groups of patients.
Methods: An observational, prospective, multicentre study in common clinical practice was designed. Treating
rheumatologists recorded patient variables, including previous and concomitant csDMARDs and GCs in a database.
The data were analysed using descriptive, inferential and multivariate statistics.
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Results: There were 1136 patients included; 21 % received the first TNF antagonist in monotherapy, 67 % received the
first TNF antagonist plus one csDMARD, and 12 % the first TNF antagonist plus two or more csDMARDs. Most patients
were female (73 %), RF+, and ACPA+, and had erosions; mean age was 53.2 (±13.0) years, and duration of disease
was 9.1 (±7.6) years. They had high activity with DAS28 of 5.8 ± 1.1, and poor physical function with HAQ of 1.43
± 0.63, and significant differences between groups in clinical variables and comorbidities; 94 % had received
treatment with GCs, MTX, LFN, or SSZ at any time before the first TNF antagonist, 5 % (n = 52) had been treated
with CLQ or HCLQ, and 1 % (n = 13) had received neither GCs nor csDMARDs. Before the first TNF antagonist, the
drugs most commonly used were GCs (78 %), MTX (50 %), LFN (44 %), and SSZ (21 %). Concomitantly with the
first TNF antagonist, 977 patients (85 %) were receiving GCs, MTX, LFN, or SSZ; 15 % (n = 173) received their first
TNF antagonist without any concomitant GCs or csDMARDs, true monotherapy, and 6 % received their first TNF
antagonist with GCs. The drug most commonly used at the time of first TNF antagonist initiation was MTX (58 %).
All treatment groups had clinically and statistically significant improvements in DAS and HAQ scores.
Effectiveness analysis (controlling for confounders) showed mean drug survival of 16.7, 20.1 and 11.7 months in
each group, respectively (p < 0.001). The model that best explained a good EULAR response included the baseline and
6-month DAS28.
Conclusions: The three groups of patiernts, have different comorbidities and disease characteristics. Treatment with
low or very low doses of GCs is common. True monotherapy with the first TNF antagonist without prednisone or
csDMARDs is infrequent. After controlling for potential confounders, effectiveness was a little different.
Keywords: RA, csDMARDs, Glucocorticoids, TNF antagonist
Background
Conventional synthetic disease-modifying antirheu-
matic drugs (csDMARDs) with or without glucocorti-
coids (GCs) are the first line of the treatment for
rheumatoid arthritis (RA) in the T2T strategy and in
most of the recommendations for RA treatment [1, 2],
and see https://www.nice.org.uk/guidance/cg79/chap-
ter/Recommendations#pharmacological-management
[3]. They can be used as sequential monotherapy or in
combination, and in all of them, methotrexate (MTX)
is the “anchor drug” [4].
Before the first biologic drug is prescribed, the pa-
tients are treated with a mean of 3–4 csDMARDs,
mainly MTX, leflunomide (LFN), sulfasalazine (SSZ)
and antimalarial drugs [5]. The main reasons for
changing this therapy are inefficacy in 30–40 % of
patients with early RA [6], and toxicity in about
10 % of patients [4–7]. Thus, between 10 % and
30 % of patients seen in clinical practice are on
inefficacious treatment or have serious comorbidi-
ties or toxicity that rule out the use of MTX, LFN,
and SSZ [8]. Some of these comorbidities are
hepatitis B or C virus infections, abnormal liver
function, severe anaemia, leukopenia or throm-
bocytopenia, severe or recurrent infections, past
history of cancer, or multiple sclerosis. Thus, up to
a third of patients are treated with biologic
disease-modifying antirheumatic drugs (bDMARDs)
in monotherapy (i.e., without any concomitant
csDMARD) [8–14].
Summaries of the product characteristics of bDMARDs,
with the exception of tocilizumab (TCZ), and clinical
practice guidelines, clinical trials meta-analyses, and
clinical practice registries recognise that a TNF antag-
onist plus csDMARD combination therapies are associ-
ated with better outcomes and with greater retention
rates. [1, 8–14]. In controlled clinical trials (CCT),
bDMARD monotherapy (except for tocilizumab (mainly
anti-TNF)) had lower efficacy and survival rates when
compared with combination therapies [13, 14]. European
League Against Rheumtism (EULAR) recommenda-
tions are clear on this point, and emphasize the
complexity of patient management in RA and the
benefits of GCs at low doses [1, 2, 15]. GCs at low
or very low doses are commonly used in clinical
practice in combination with csDMARDs, particu-
larly in patients with early disease, and there is a
growing body of evidence supporting their role as
cost-effective csDMARDs [16, 17].
As TNF antagonist are frequently used in monother-
apy for reasons of safety in patients with adult-onset RA
treated within the Andalusian Health Service, a registry
was designed with the following objectives:
1. To understand and compare clinical features
of patients who receive the first TNF antagonist
monotherapy, against the patients who receive
the first TNF antagonist plus one csDMARD,
against the patients who receive the first TNF
antagonist plus two or more csDMARDs.
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2. To determine the prescription patterns of
csDMARDs with high efficacy (MTX, LFN,
and SSZ) and GCs before the first TNF antagonist
prescription.
3. To identify csDMARD and GC prescription
patterns at initiation of the first TNF antagonist.
4. To assess the effectiveness of the first TNF
antagonist in the three groups of patients, using
EULAR response, and improvement in health
assessment questionnaire (HAQ) scores, survival
curves and multiple logistic regression analysis.
Methods
Design
This was an observational, prospective, multicentre, ana-
lytical study.
Inclusion criteria
Inclusion criteria were patients over 18 years of
age, able to complete follow-up questionnaires, ful-
filling criteria for RA published in 1987 [18], and
treated with at least one dose of any TNF antagon-
ist (adalimumab, infliximab, etanercept) approved
for use in patients with moderately active RA in ac-
cordance with the Second Consensus Document on
the Use of Biologic Agents in RA of the Spanish
Rheumatology Society [19]. This consensus docu-
ment states that a patient should have failed treat-
ment with two or more csDMARDs for at least
3 months, or have developed toxicity to the admin-
istered drugs in order to initiate therapy with a
TNF antagonist.
Patients with diagnoses other than RA, duplicated
registration, or those whose data were insufficient to
calculate clinically relevant outcomes were excluded
from the study. The study was approved by the Ethical
and Human Research Committee of the Virgen de la
Macarena Hospital Area, and conducted in accordance
with The Declaration of Helsinki [20] and the Good
Clinical Practice Guidelines (http://www.ich.org/products/
guidelines/efficacy/efficacy-single/article/good-clinical-prac-
tice.html). The SAS, the public healthcare system in the
Autonomous Community of Andalusia, prescribes and
reimburses approximately 80 % of bDMARDS, while
the remaining 20 % are prescribed by private medical
clinics. Registry completion was mandatory to obtain
the bDMARD from the SAS. All rheumatology depart-
ments of Andalusia were invited to take part in the
registry. Participating rheumatologists received training
on the study objectives and on the different operative
definitions used in this project. Inefficacy was defined
according to the judgement of the treating rheumatolo-
gist. Serious adverse events were defined as death,
hospitalization, or life-threatening for the patient. Non-
serious adverse events were defined as non-serious clin-
ical conditions leading to discontinuation of therapy
with DMARDs.
A treating rheumatologist and/or a research fellow at
each centre had access to a specifically designed website,
and prospectively recorded the following information:
sociodemographic and RA-related variables, with par-
ticular emphasis on the patient’s disease activity, physical
function, previous and concomitant therapy with
csDMARDs and GCs, current therapy with csDMARDs
and GCs at initiation of therapy with the biologic agent,
reasons for discontinuation of csDMARDs or GCs or
switch, and comorbidities. The relevant comorbidities
were: secondary Sjögren’s syndrome, interstitial lung dis-
ease, rheumatoid vasculitis, amyloidosis, latent or active
tuberculosis, past history of tuberculosis, purified pro-
tein derivative skin reaction (PPD) test, hepatitis B or C
infection, HIV infection, other severe or recurrent in-
fections, previous cancer, history of heart failure, and
demyelinating disease. The number of comorbidities
and mortality were also registered.
Patients were divided into three groups according to
the type of treatment they were receiving: first TNF an-
tagonist monotherapy; first TNF antagonist plus one
csDMARD; and a first TNF antagonist plus two or more
csDMARDs. From the website the data were recorded in
an Excel spreadsheet. The Excel spreadsheet was cleaned
and the data were verified with the clinical charts, for
subsequent processing using STATA v 10.0 software.
Central tendency and dispersion measures were calcu-
lated in the first phase of the analysis and graphic analysis
was performed. The three groups were subsequently com-
pared using analysis of variance (ANOVA) for quantitative
variables with a Gaussian distribution and/or the Kruskal
−Wallis test for quantitative variables with a non-
Gaussian distribution or ordinal variables. In the case
of significant differences, the Mann–Whitney U test or
Student’s t test with Bonferroni correction for multiple
comparisons was used to analyse specific differences
between two of the three groups. For nominal variables,
contingency tables were produced and the chi-squared
or fisher exact test was applied. In all cases the most
pragmatic statistical analysis was performed.
For effectiveness analyses the primary outcome was
good/moderate EULAR response with a first anti-TNF
therapy, which was defined as the length of time the pa-
tients continued to receive their first anti-TNF therapy;
patients were censored at the treatment stop date, date
of death or date of the last follow up, whichever came
first. Kaplan–Meier survival curves were used to de-
scribe persistence with anti-TNF therapy. Also logistic
regression was used to identify predictive models of
EULAR good response. Survival analysis and logistic re-
gression were performed in a crude way, and adjusted by
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age, sex, disease duration, rheumatoid factor (RF) positiv-
ity, anti-citrullinated protein antibodies (ACPA) positivity,
baseline disease activity score in 28 joints (DAS28), base-
line health assessment questionnaire (HAQ), erosions,
and number of comorbidities. In a third phase a propen-
sity score was created using the same variables in order to
adjust for severity of the disease.
Missing values were imputed using three techniques:
(1) using the mean value of the previous observations,
(2) using the value of the last observation, and (3) look-
ing at the pattern of missing values in the time series,
and calculating these values.
Results
The registry was active from 15 May 2008 to 31 March
31 2012. During this period, 20 physicians from 18
rheumatology departments, and 2 internal medicine de-
partments recorded data from 1237 patients treated with
their first biologic agent. There were 101 patients (8 %)
excluded from the registry for various reasons: 47 pa-
tients did not initiate treatment, 28 had duplicate regis-
trations, 14 patients started rituximab, 6 patients had
received abatacept as their first biologic agent, and 6
were excluded due to lack of indication. Results of 1136
patients with adult-onset RA are presented. Of these
patients, 21 % received their first TNF antagonist in
monotherapy, 67 % received their first TNF antagonist
plus one csDMARD, and 12 % were treated with a first
TNF antagonist plus two or more csDMARDs (Table 1).
Differences between groups were observed in patient
characteristics, percentages of patients with joint arthro-
plasty, number of comorbidities, positive hepatitis virus
antibodies, and positive tuberculin test results (Table 1).
In addition to the comorbidities shown in the table,
there were 13 patients (1 %) with rheumatoid vasculitis,
of whom 3 (1 %) were patients in the group treated with
the first TNF antagonist in monotherapy, 9 (1 %) were
in the group treated with the first TNF antagonist plus
one csDMARD, and 1 (0.7 %) was in the group treated
with the first TNF antagonist plus two or more
csDMARDs (p = 0.8); in the same groups respectively,
there were 2 patients (0.8 %), 4 patients (0.5 %), and 0
patients (0 %) with amyloidosis, respectively p = 0.5), and
1 patient (0.4 %), 4 patients (0.5 %), 0 patients (0 %) with
previous heart failure (p = 0.6). Previous tuberculosis was
identified in 6 patients (3 %), 24 patients (3 %) and 0 pa-
tients (0 %), respectively (p = 0.08). In the group treated
with the first TNF antagonist plus one csDMARD there
was one patient with HIV infection and one with demye-
linating disease. Neither of these patients died.
Types of first TNF antagonist are shown on Fig. 1. As
expected, and in accordance with the summaries of
product characteristics and treatment recommendations,
most patients received etanercept as their first TNF
antagonist monotherapy, and significant differences were
observed in the type of TNF antagonist used within each
treatment group, p < 0.0001.
Among all patients, 94 % had received treatment with
GCs, MTX, LFN, or SSZ at any time before the TNF an-
tagonist prescription (Table 2); 6 % had not received
these drugs, 5 % (n = 52) had been treated with antimal-
arial agents, and only 1 % (n = 13) had received neither
GCs nor csDMARDs. Most patients had received com-
bination therapies (n = 761; 66 %). The drugs most com-
monly used in monotherapy or in combination were
GCs, either prednisone (PDN) or equivalent, used in
78 % of patients, followed by MTX (50 %), LFN (44 %),
and SSZ (21 %). The most frequent combination was
GC plus MTX, LFN, or SSZ, used in 31 % (n = 357) of
patients, followed by a GC plus two csDMARD 23 %
(n = 267). Combinations of csDMARDs without GCs
were less frequent: 4 % of patients were treated with
MTX + SSZ + LFN + PDN. Inefficacy of the drug was
the primary reason for MTX, LFN, and SSZ discontinu-
ation in over half of the patients. Non-serious adverse
events were the second reason for discontinuation of
these csDMARDs in 40 %, 36 %, and 40 % of patients,
respectively. The frequency of serious adverse events
was very low.
MTX, LFN, SSZ, and GC prescription patterns at the
time of initiation of the first TNF antagonist are shown
on Table 3. At initiation of the first TNF antagonist, 977
patients (85 %) were receiving concomitant GCs, MTX,
LFN, or SSZ: 15 % (173 patients) received their first
TNF antagonist without any concomitant GC or
csDMARD, i.e., true monotherapy, and 6 % received
their first TNF antagonist with GCs. The drug most
commonly used at the time of first TNF antagonist initi-
ation was MTX alone or in combination (58 %), followed
by PDN (45 %), LFN (24 %), SSZ (5 %), and anti-malarial
agents (1 %). Over 80 % of patients were using non-
steroidal anti-inflammatory drugs (NSAIDs). Mean doses
of PDN, MTX, and LFN were the commonly used doses.
Mean duration of the previous courses with csDMARD
therapies before the first TNF antagonist were 2 years
for MTX, and less than 1 year for LFN.
Effectiveness data are shown in Table 4. With regard
to disease activity, all treatment groups showed clinically
significant improvements in final vs. baseline DAS. Phys-
ical function data assessed by the HAQ scores were sig-
nificantly different between groups at the final vs. the
baseline assessment, and the TNF antagonist plus two
or more csDMARDs group had the poorest physical
function. The percentage of patients with completed
visits were 56 %, 51 %, and 60 % in each group, respect-
ively; p = 0.4. The number and causes of loss of follow
up were the same in the three groups except for ad-
verse events. The adverse events were more frequent in
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the patients treated with the first TNF antagonist plus
one csDMARD, with marginal statistical significance.
Loss of follow up due to patient´s decision were due to
intention to become pregnant, change of city, addition
of other inter-current disease, and in some cases the
reasons were unknown.
Percentages of patients with good EULAR response
were 29 % in the first TNF antagonist monotherapy
group, 29 % in the first TNF antagonist plus one
csDMARD group, and 43 % in the first TNF antagonist
plus two or more csDMARDs group (p = 0.07). Percent-
ages of patients with moderate EULAR response were
50 %, 52 %, and 51 %, respectively, and marginal statis-
tically significant differences were observed (p = 0.07)
(Fig. 2). Percentages of patients with a final HAQ score
≤ 1 were 73 %, 63 %, and 54 %, respectively (p = 0.01)
(Fig. 3).
On crude analysis of drug survival, for TNF antagonist
survival the mean (25th to 75th percentiles) was 33.3
(16.8–40.7) months in the TNF antagonist monotherapy
group, 30.4 (16.6–41.4) months in the TNF antagonist
plus one csDMARD group, and 34.2 (8.1–40.8) months
in the TNF antagonist plus two or more csDMARDs
group (p = 0.07) (Fig. 4). When this analysis was adjusted
Table 1 Rheumatoid arthritis characteristics at baseline
First TNF antagonist
monotherapy
First TNF antagonist plus
one csDMARD
First TNF antagonist plus
two or more csDMARDs
Total P*
n, % 234 21 766 67 136 12 1.136 100
Gender, female n, % 175 75 557 73 99 73 831 73 0.8
Rheumatoid factor (RF)+ n, % 183 78 619 81 104 77 906 80 0.4
ACPA + n, % * 47/71 66 330/431 77 47/70 67 424/ 572 74 0.06
RF- and ACPA- n, % 12 5 64 8 14 10 90 8 0.07
Erosions n, % 195 83 622 81 100 74 917 81 0.05
Rheumatoid nodules n, % 50 21 189 25 18 13 257 23 0.01
Joint arthroplasty n, % 15 6 66 9 3 2 84 7 0.02
Number of comorbidities n, %
0 67 30 159 22 51 42 277 26 0.003
1 32 14 72 10 12 10 116 11
≥2 124 56 481 68 57 48 662 63
Anti-hepatitis B antibody+ n, % 2/47 4 7/194 4 0/26 0 9/267 3 0.2
Anti-hepatitis C antibody+ n, % 6/46 13 6/195 3 2/26 8 14/267 5 0.05
PPD skin reaction + (≥5 mm) n, % 24 10 120 16 17 13 161/1.112 14 0.09
Secondary Sjögren’s syndrome n, % 44 19 128 17 17 12 189 17 0.2
Interstitial lung disease n, % 16 7 25 3 1 0.7 42 4 0.007
Recurrent infections n, % 5 2 11 1 1 0.7 17 2 0.54
Past cancer n, % 4 2 5 0.6 0 0 9 0.8 0.1
Mean ± SD
Age (years) mean ± SD 55.9 ±13.7 52.8 ±13.4 50 .7 ±11.1 53.2 ±13.3 0.0001
Duration of disease (years) mean ± SD 9.4 ±8.0 9.0 ±7.5 8.8 ±7.3 9.1 ±7.6 0.8
Number of comorbidities mean ± SD 2.2 ±2.3 2.7 ±2.4 1.9 ±2.3 2.5 ±2.4 0.0001
Tender joint count (0–28) mean ± SD 10.9 ±6.4 10.3 ±6.6 11.6 ±6.9 10.6 ±6.6 0.0003
Swollen joint count (0–28) mean ± SD 9.0 ±6.1 7.9 ±5.5 8.5 ±5.8 8.2 ±5.7 0.02
Pain visual analogue scale (0–100) mean ± SD 61.9 ±19.3 63.5 ±22.2 66.0 ±20.8 63.4 ±21.5 0.01
DAS28-ESR mean ± SD 5.9 ±1.0 5.7 ±1.1 5.7 ±1.0 5.8 ±1.1 0.03
HAQ score (0–3) mean ± SD 1.40 ±0.58 1.44 ±0.65 1.6 ±0.59 1.46 ±0.63 0.0003
ESR (mm) mean ± SD 45.7 ±24.7 42.1 ±25.8 32.7 ±21.5 41.8 ±25.3 0.0001
C-reactive protein (mg/L) mean ± SD 19.3 ±21.4 15.7 ±21.5 15.8 ±19.4 16.5 ±21.2 0.0001
csDMARD conventional synthetic disease-modifying antirheumatic drug, ACPA anti-citrullianted protein antibodies, PPD purified protein derivative skin reaction,
DAS28-ESR disease activity score in 28 joints-erythrocyte sedimentation rate, HAQ health assessment questionnaire.
*This variable was not assessed in all patients
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for age, gender, number of comorbidities, and disease
duration, thus, controlling for these potential con-
founders, there were statistical differences in survival
between the three groups, with mean TNF survival of
16.7 (11.8–24.1), 20.1 (11.3–31.3), and 10,5 (6.1–29.6)
months, respectively (p < 0.001) (Fig. 5).
Finally, in the logistic regression the model that best
explained a good EULAR response included the baseline
DAS28 and the 6-month DAS28 (p <0.0001 and R2 0.8).
The model was not modified after adjustment for age,
gender, disease duration, and treatment group. The
model followed a similar pattern using the different
techniques for handle missing values (data not shown).
Discussion
This was an observational, prospective, multicentre study
of a cohort of patients with RA treated with their first
TNF antagonist in standard clinical practice within the
Andalusian Health Services. The registry included 90 % of
prescriptions of biologic agents issued in this community.
We observed differences in the characteristics of patients
who received their first TNF antagonist in monotherapy
or in combination with csDMARDs, and found that pre-
scriptions were largely influenced not only by accessibility
to biological drugs within the health system, but also by
the clinical characteristics of the patients, particularly co-
morbidities and drug intolerance, and by the previous
experience of the rheumatologist [14].
Patients in the three groups had differences in the
type and number of comorbidities. As we know since
the time of Hippocrates, there are patients, not dis-
eases, and this is the art of medicine reflected in
DMARDs prescription patterns, in spite of treatment
schedules that are defined in Spain in summaries of
product characteristics and their respective Clinical
Practice Guidelines [1, 2], (https://www.nice.org.uk/
guidance/cg79/chapter/Recommendations#pharmacolo-
gical-management), [3, 19]. The data are in agreement
with data recently reported by other registries and pub-
lications [5, 8–14].
In our study, before initiation of their first TNF antag-
onist, only 1 % of patients had not received GCs, MTX,
LFN, SSZ, and/or CLQ/HCLQ. PDN, either as mono-
therapy or in combination with other csDMARDs was
the most commonly prescribed drug (78 %), followed by
MTX (50 %), and LFN (44 %); SSZ (21 %) was only used
in a small number of cases. Rheumatologists prefer
combinations of csDMARDs with PDN, and the most
frequently prescribed for combination therapy is MTX
[4–7, 12–15]. This high level of prescription of PDN at
low or very low doses, in monotherapy or in combin-
ation with csDMARDs or a TNF antagonist, is a conse-
quence of the effectiveness of this drug for reducing
signs and symptoms of the disease. The advantages of
PDN include improved patient-reported outcomes and
lower disease activity levels, its benefit on radiological
evidence of disease progression, and its very favourable
efficacy/toxicity ratio producing very low rates of ser-
ious adverse events, and no serious adverse events re-
lated to this low or very low dose.
Fig. 1 First prescribed biologic disease-modifying antirheumatic drug (bDMARD). csDMARD conventional synthetic DMARD
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Table 2 Prescription patterns of csDMARDs (MTX, LFN y SSZ) and GCs before the firs TNF antagonist




First TNF antagonist plus
two or more csDMARDs
Total P*
n % n % n % n %
234 21 766 67 136 12 1.136 100
Previous use of DMARDs (MTX, LFN, SSZ) and/or PDN) (n , %) 229 98 712 93 130 96 1,071 94
None (n, %) 5 2 54 7 6 4 65 6 0.0001
One (n, %) < 0.001
PDN 8 3 139 18 76 56 223 20
MTX + PDN 47 20 122 16 9 7 178 16
LFN + PDN 17 7 106 14 8 6 131 11
LFN 1 0.4 41 5 2 1 44 4
SSZ + PDN 3 1 29 4 12 9 44 4
MTX 5 2 33 4 1 0.7 39 3
SSZ 4 2 11 1 1 0.7 16 1
Total (MTX, LFN, SSZ) 77 33 342 45 33 24 452 40
Total PDN 75 32 396 52 105 77 576 51
Two (n, %) < 0.001
LFN + MTX + PDN 67 29 89 12 12 9 168 15
LFN + MTX 16 7 26 3 2 1 44 4
SSZ + MTX + PDN 15 6 31 4 3 2 49 4
SSZ + LFN + PDN 4 2 38 5 2 1 44 4
SSZ + MTX 8 3 14 2 1 0.7 23 2
SSZ + LFN 1 0.4 6 0.7 0 0 7 0.6
Total (MTX, LFN, SSZ) 111 48 204 27 20 15 335 30
Total PDN 86 37 158 21 17 12 218 20
Three (n, %) < 0.001
MTX + SSZ + LFN 6 2 6 0.7 1 0.7 13 1
MTX + SSZ + LFN + PDN 27 12 21 3 0 0 48 4
Total (MTX, LFN, SSZ) 33 14 27 3 1 0.7 61 5
Total PDN 27 12 21 3 0 3 48 4
Previous exposure to MTX (n, %) 191 83 343 45 29 21 563 50 0.03
Reason for discontinuation
Inefficacy 92 48 212 62 16 55 320 57
Non-serious adverse event 91 48 121 35 13 45 225 40
Serious adverse event 8 4 10 3 0 0 18 3
Previous exposure to LFN (n, %) 139 60 338 44 27 20 505 44 < 0.0001
Reason for discontinuation
Inefficacy 64 46 229 68 16 59 309 62
Non-serious adverse event 69 50 104 31 11 41 184 36
Serious adverse event 6 4 5 1 0 0 11 2
Previous exposure to SSZ (n, %) 68 29 157 20 20 15 245 21 0.0001
Reason for discontinuation (n, %)
Inefficacy 17 50 46 63 1 33 64 26
Non-serious adverse event 18 47 26 36 2 66 46 19
Serious adverse event 0 0 1 1 0 0 2 0.8
Previous exposure to PDN ( n,%) 188 80 575 75 122 90 885 78 < 0.0001
csDMARD conventional synthetic disease-modifying antirheumatic drug, DMARD disease-modifying antirheumatic drug, MTX methotrexate, LFN leflunomide,
SSZ sulfasalazine, PDN prednisone
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According to the literature, low or very low doses of
steroids are used the same way as any other csDMARDs,
and should be considered as such [8–12, 16, 17]. The
frequency of baseline use of steroids found in several
registries of patients with RA receiving bDMARDs are
the following: 27 % in the Swiss Registry [9], 22 % in the
Danish Registry [10], and in accordance with a review
including various countries [11], figures range from 38 %
to 84 % in Germany (84 %), Spain (52 %), Sweden
(51 %), UK (44 %), and USA (38 %) (CORRONA data-
base). Considering these data, TNF antagonists are not
really given in monotherapy, due to the high frequency
of GC use in patients treated with TNF antagonists in
monotherapy. Unfortunately, this study did not include
data on radiographic progression, so the real value of
GCs as csDMARDs cannot be assessed.
The low use of SSZ in Spain may be explained by the
enteric coating of the formulation. This is different from
the coating used in other European countries, and its ef-
ficacy is lower than that reported in studies conducted
in Northern Europe. As a consequence, SSZ is only used
after other csDMARDs, namely MTX, LFN, and CLQ/
HCLQ [21]. Our results may be influenced by our re-
quirement that during the period in which the study was
Table 3 Prescription patterns of concomitant MTX, LFN, SSZ, and PDN with the first TNF antagonist
Current treatment with synthetic





First TNF antagonist plus
two or more csDMARDs
Total P*
n % n % n % n %
234 21 766 67 136 12 1.136 100
None (n, %) 172 73
PDN (n, %) 62 26 336 44 115 84 513 45 0.0001
MTX (n, %) 364 47 <
0.0001
MTX + PDN (n, %) 189 25 <
0.0001
LFN + PDN (n, %) 129 17 <
0.0001
LFN (n, %) 57 7 <
0.0001
SSZ + PDN (n, %) 9 1 <
0.0001
SSZ (n, %) 5 0.6 <
0.0001
Combinations (n, %) <
0.0001
MTX + LFN + PDN 66 48
MTX + SSZ + PDN 24 17
MTX + SSZ 12 9
LFN + CLQ + PDN 8 6
MTX + SSZ + HCLQ + PDN 5 4
MTX + LFN 4 3
Others 17 13
NSAIDs (n, %) 201 86 673 88 127 93 1.013 88 0.09
Mean SD Mean SD Mean SD Mean SD
Current PDN dose, mg/day (mean ± SD) 10.7 ±5.6 9.6 ±6.7 10.0 ±7.5 9.8 ±6.6 0.002
Current MTX dose, mg/week (mean ± SD) 0 0 15.3 ±4.8 16.0 4.7 15.5 4.8 0.08
Duration of current treatment with MTX (months) (mean ± SD) 31.0 32.2 21.5 23.6 27.6 28.6 0.0001
Current LFN dose, mg/day (mean ± SD) 0 0 18.8 3.1 15.6 4.9 17.8 4.0 <
0.0001
Duration of current treatment with LFN
(months) (mean ± SD)
12.9 19.0 9.4 9.9 12.0 16.5 0.5
Follow up, (years) (mean ± SD) 2.1 1.0 1.8 1.0 1.6 1.1 1.8 1.1 0.0001
csDMARD conventional synthetic disease-modifying antirheumatic drug, DMARD disease-modifying antirheumatic drug, MTX methotrexate, LFN leflunomide,
SSZ sulfasalazine, PDN prednisone, NDAID non-steroidal anti-inflammatory drug
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conducted, patients had to have failed to respond to at
least two csDMARDs in order to be prescribed a
bDMARD [3, 19]. A lack of efficacy, followed by
mild csDMARD toxicity (30–40 %), were the pri-
mary reasons for the participating rheumatologists
to request bDMARDs. Severe toxicity was very in-
frequent (< 3 %).
With regard to GCs and csDMARDs prescription pat-
terns, at the time of initiation of the first TNF antagonist
most patients were receiving monotherapy or
Table 4 Rresponse in patients with rheumatoid arthritis at 6 months and follow-up data
Treatment with synthetic DMARDs First TNF antagonist
monotherapy
First TNF antagonist plus
one csDMARD
First TNF antagonist plus two or
more csDMARDs
Total Pp*
n, % 234 21 766 67 136 12 1.136 100
Baseline DAS28 score (mean ± SD) 5.9 1.0 5.7 1.1 5.7 1.0 5.8 1.1 0.2
Final DAS28 score (mean ± SD) 3.56 1.54 3.39 1.52 3.6 1.3 3.4 1.5 0.8
Difference in DAS28 score (mean ± SD) 1.6 0.7 1.6 0.7 1.7 0.6 1.6 0.7 0.4
Baseline HAQ score (mean ± SD) 1.40 0.58 1.44 0.65 1.63 0.59 1.461 0.633 0.002
Final HAQ score (mean ± SD) 0.83 0.71 0.93 0.76 1.08 0.74 0.930 0.752 0.005
Difference in HAQ score (mean ± SD) 0.60 0.69 0.51 0.75 0.60 0.70 0.545 0.734 0.1
Follow up
Completed last visit (n, %) 132 56 391 51 82 60 605 53 0.46
Loss of follow up (n, %) 102 44 375 49 54 40 531 47 0.07
Reasons
Adverse event 33 32 174 46 16 30 223 42 0.001
Inefficacy 30 29 87 23 12 22 129 24 0.5
Patient decision 7 7 15 4 3 5 25 5 0.6
Unknown 32 32 99 27 23 43 154 29 0.4
*P value for between-group comparisons. Differences between groups in baseline vs. final disease activity score in 28 joints (DAS) and health assessment questionnaire
(HAQ) scores were statistically significant, p < 0.001. csDMARD conventional synthetic disease-modifying antirheumatic drug, DMARD disease-modifying antirheumatic drug
Fig. 2 Response according to European League Against Rheumatism Criteria. csDMARD conventional synthetic disease-modifying antirheumatic drug,
bDMARD biologic disease-modifying antirheumatic drug
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combination therapy with MTX, followed by PDN, LFN,
and SSZ. The decreased frequency of GC treatment,
from 78 % to 45 %, needs to be emphasized. Only 15 %
of patients received the first TNF antagonist without
concomitant csDMARDs or GCs. Almost one third
(27 %) of patients who received their first TNF antagon-
ist in monotherapy were being treated with PDN as the
sole medication. Again, the data show that low or very
low doses of PDN were a commonly used treatment at
the time of initiation of the first TNF antagonist. GC,
Fig. 4 Crude survival life table. csDMARD conventional synthetic disease-modifying antirheumatic drug
Fig. 3 Percentages of patients with a health assessment questionnaire (HAQ) score > 1 and HAQ score ≤ 1. csDMARD conventional synthetic
disease-modifying antirheumatic drug
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MTX, and LFN doses were similar to those recorded in
other registries and observational studies [5, 8–12, 14].
It should be noted that a smaller subgroup of patients
(those who received their first TNF antagonist plus two
or more csDMARDs) were treated with different GCs,
and csDMARD combinations. The most commonly used
regimen was combination treatment with PDN plus one
or more csDMARDs.
It should be emphasized that patients achieved adequate
responses irrespective of the treatment they received.
There were no differences between groups in improve-
ment in disease activity after starting the biologic agent,
but poorer levels of physical function were observed in
the baseline and final assessments of those patients
treated with the first TNF antagonist plus two or more
csDMARDs. After adjustment for potential con-
founders, the survival analysis showed the best survival
rates in the group treated with the first TNF antagonist
plus one csDMARD.
This study had advantages that should also be pointed
out. First, the study was based on data from standard
clinical practice that included 90 % of biologic drug pre-
scriptions. This prospective study was conducted in the
setting of specialized rheumatology care and was spe-
cially designed to determine prescription patterns of
GCs, csDMARDs, and the first TNF antagonist. Further-
more, patients’ clinical characteristics were similar to
those observed in other European registries of patients
with RA.
Unfortunately, due to the large number of patients
lost to follow up, effectiveness data should be viewed
with reservation, even though no statistically or clinic-
ally relevant differences were found in a comparison of
sociodemographic and RA disease characteristics be-
tween patients lost to follow up vs. patients who con-
tinued (data not shown). The different statistical
techniques used to handle missing values also showed
different results. We know that the effectiveness data
are not fully robust, as they might reflect a cohort of
survivors. Another limitation is that, currently, many of
these patients who cannot receive csDMARDs are
treated with TCZ; thus, the external validity of the data
is limited to patients who cannot receive TCZ. The
third handicap is the lack of evaluation of radiographic
outcome.
Conclusions
Patients receiving the first TNF antagonist monotherapy,
the first TNF antagonist plus one csDMARD, and the first
TNF antagonist plus two or more csDMARDs are patients
with different comorbidities and disease characteristics,
which influence the type of drugs they receive. Low or
very low doses of GCs are frequently used. Combination
treatments with PDN plus csDMARDs are more fre-
quently used by rheumatologists, compared to csDMARD
monotherapy or other combinations. In most cases,
these agents are discontinued due to lack of efficacy,
Fig. 5 Adjusted survival life table. csDMARD conventional synthetic disease-modifying antirheumatic drug
Hernández-Cruz et al. Arthritis Research & Therapy  (2016) 18:259 Page 11 of 13
requiring the introduction of TNF antagonist therapy.
With the first TNF antagonist, PDN in combination
with one csDMARD is used in almost half of the cases.
Monotherapy with a TNF antagonist without PDN or
csDMARDs is uncommon. In spite of their different
characteristics, patients receiving the first TNF antagonist
monotherapy, the first TNF antagonist plus one
csDMARD, and the first TNF antagonist plus two or more
csDMARDs obtain clinical responses in terms of activity
and physical function measured by an acceptable HAQ
score. Survival differed in the three groups of patients.
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